Abstract 357P
Background
Advanced Head and neck cancer despite multimodal treatment is associated with disfigurement, extreme pain, and psychological distress. To study the effects of a multimodal palliative approach involving psychological counselling, psychometric dug therapy and pain-relieving blocks to ameliorate the total pain state of such patient during end of life care.
Methods
This is a prospective, single-arm observational study conducted on 20 head and neck cancer patients, from January 2015 to December 2018. Patients who were on palliative treatment were processed for self-report of severe psychological distress and intractable pain by means of innovative distress score and quality of life index and the numeric pain rating scale and given combination therapy with antidepressants, antipsychotics, pain killers and neurolytic blocks along with repeated counselling sessions.
Results
20 patients were included in this study, of which 66.6 % were males and 33.3% were female. Age range was 44-79 years and they had mean pain scores of 7.61 (SD 1.577) before the intervention and mean distress scores of 8.33 (SD 1.237) suffering for a duration of 72.5 days (SD 24.81). A significant reduction in pain was noted by a decrease in mean Numeric rating scale to 2.83 (SD 0.618) and extension of the mean duration of analgesia to 24.33 days (SD 6.84) and reduction in distress score to 3.78 (SD 0.732). Pre- and post-procedure mean morphine requirement was also significantly reduced, at the end of 2 weeks. Significant easing of distress and improvement in performance was observed in all patients.
Conclusions
The application of a multimodal palliative approach to progressive head and neck cancer patients is an easy, safe, and cost-effective method to improve quality of life. Medical oncologists must be sensitized to elicit and measure the distress in such patients. Counseling sessions and pharmacotherapy, if indicated, are very effective in the care of such patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract